Roflumilast Foam 0.3%

DRUG4 trials

Sponsors

Arcutis Biotherapeutics, Inc., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Conditions

Plaque PsoriasisScalp PsoriasisSeborrheic Dermatitis

Phase 2

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

CompletedNCT04091646

Arcutis Biotherapeutics, Inc.Seborrheic Dermatitis

Start: 2019-12-04End: 2020-08-21Updated: 2023-07-03

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

CompletedNCT04128007

Arcutis Biotherapeutics, Inc.Plaque Psoriasis

Start: 2020-01-13End: 2020-09-25Updated: 2022-10-26

Phase 3

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

CompletedNCT05028582

Arcutis Biotherapeutics, Inc.Scalp Psoriasis

Start: 2021-08-24End: 2022-06-03Updated: 2025-07-17

Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis

Not yet recruitingNCT07683806

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Seborrheic Dermatitis

Start: 2026-08-24End: 2027-08-03Target: 309Updated: 2026-08-21

Related Papers

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body

JAMA Dermatology2025-05-075 citations

Patient-Reported Outcomes with Roflumilast Foam 0.3% in Patients with Psoriasis of the Scalp and Body in the Phase 3 ARRECTOR Trial

SKIN The Journal of Cutaneous Medicine2025-03-17

504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis

British Journal of Dermatology2024-02-01

Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis

SKIN The Journal of Cutaneous Medicine2024-01-16

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis

JAMA Dermatology2023-05-0332 citations

Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial

SKIN The Journal of Cutaneous Medicine2023-03-131 citations